Sakar Healthcare Limited — Investor Meet, 17-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sakar Healthcare reported robust Q3 FY26 financial results with revenue up 62% to INR 70.34 Cr and PAT soaring 126% to INR 10.25 Cr, achieving 26% EBITDA margins. The oncology business, which generated INR 31 Cr in Q3, is a key growth driver. Management anticipates 60-70% oncology revenue growth for FY27, targeting 30% EBITDA margins. The EU GMP facility secured EU product supply approval, and 10 tech-transfer molecules, including Imatinib with Intas/Accord, are set for EU market supply commencing soon. The company is confident in leveraging its integrated oncology capabilities and strategic partnerships for sustained value creation.